The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind

Author(s): Roberta Ricciarelli*, Ernesto Fedele*

Journal Name: Current Neuropharmacology

Volume 15 , Issue 6 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer’s disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer’s disease research in the future.

Keywords: Alzheimer's disease, beta amyloid, clinical trials, LTP, memory, anti-amyloid therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 30 July, 2017
Page: [926 - 935]
Pages: 10
DOI: 10.2174/1570159X15666170116143743
Price: $65

Article Metrics

PDF: 51
HTML: 11